Yong-Jin Wu
Research Subjects
Yong-Jin Wu has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
Huan He
Research and Development, Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, USA
10 shared publicationsJason Guernon
Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492-7660, USA
9 shared publicationsJohn E. Macor
Bristol-Myers Squibb, Wallingford, Connecticut 06492, United States
9 shared publicationsLorin A. Thompson
Bristol-Myers Squibb, Wallingford, Connecticut 06492, United States
9 shared publicationsRamkumar Rajamani
Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492-7660, USA
7 shared publicationsRonald J. Knox
Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492-7660, USA
7 shared publications
Latest Publications
- 10 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (14) , 16143-16208
Application of Bioisosteres in the Design and Discovery of FDA-Approved Drugs and Advanced Clinical Candidates
Since its introduction in 1951, bioisosterism has become a cornerstone strategy in drug design and development, enabling chemists to rationally modify molecular structures to optimize biological and physicochemical properties. In this perspective, we examine 57 FDA-approved drugs and 18 advanced drug candidates wherein bioisosteric replacements were successfully employed to address a range of developability challenges encountered during lead optimization. These strategic substitutions have led to significant improvements in potency, selectivity, solubility, and metabolic stability, while simultaneously mitigating issues related to lipophilicity, plasma protein binding, and the formation of reactive metabolites. Together, these examples highlight the enduring impact of bioisosterism as a versatile tool for fine-tuning drug candidates and overcoming the multifaceted challenges of modern medicinal chemistry.
- 10 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (14) , 16143-16208
Application of Bioisosteres in the Design and Discovery of FDA-Approved Drugs and Advanced Clinical Candidates
Since its introduction in 1951, bioisosterism has become a cornerstone strategy in drug design and development, enabling chemists to rationally modify molecular structures to optimize biological and physicochemical properties. In this perspective, we examine 57 FDA-approved drugs and 18 advanced drug candidates wherein bioisosteric replacements were successfully employed to address a range of developability challenges encountered during lead optimization. These strategic substitutions have led to significant improvements in potency, selectivity, solubility, and metabolic stability, while simultaneously mitigating issues related to lipophilicity, plasma protein binding, and the formation of reactive metabolites. Together, these examples highlight the enduring impact of bioisosterism as a versatile tool for fine-tuning drug candidates and overcoming the multifaceted challenges of modern medicinal chemistry.
- 2 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5935-5943
Optimization of α-Fluoro, β-Heteroaryl Acrylamide Warheads for KRAS G12C Active-State Inhibition
We provide herein a detailed investigation of the warhead reactivity and pharmaceutical properties of a novel α-fluoro, β-heteroaryl acrylamide class of covalent warhead in the context of KRASG12C active-state inhibition. Unlike traditional unsubstituted acrylamide warheads, which undergo conjugate addition with cysteine at the β-position, these acrylamides react at the α-position in a vinylogous nucleophilic aromatic substitution (SNAr) transformation. Systematic examination of pyridine warhead substitutions and bioisosteric replacements elucidated a dependence of these warheads' reactivity on heterocycle basicity in addition to electrophilicity. In vitro characterization revealed the effects of heterocycle identity on cellular potency, free fraction, permeability, and efflux ratio. These lessons informed in vivo studies, culminating in the discovery of a lead molecule that showed low clearance across species and robust efficacy in a mouse xenograft model.
- 2 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5935-5943
Optimization of α-Fluoro, β-Heteroaryl Acrylamide Warheads for KRAS G12C Active-State Inhibition
We provide herein a detailed investigation of the warhead reactivity and pharmaceutical properties of a novel α-fluoro, β-heteroaryl acrylamide class of covalent warhead in the context of KRASG12C active-state inhibition. Unlike traditional unsubstituted acrylamide warheads, which undergo conjugate addition with cysteine at the β-position, these acrylamides react at the α-position in a vinylogous nucleophilic aromatic substitution (SNAr) transformation. Systematic examination of pyridine warhead substitutions and bioisosteric replacements elucidated a dependence of these warheads' reactivity on heterocycle basicity in addition to electrophilicity. In vitro characterization revealed the effects of heterocycle identity on cellular potency, free fraction, permeability, and efflux ratio. These lessons informed in vivo studies, culminating in the discovery of a lead molecule that showed low clearance across species and robust efficacy in a mouse xenograft model.
- 26 June 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (27) , 18616-18625
Cu-Catalyzed Amination of Base-Sensitive Aryl Bromides and the Chemoselective N- and O-Arylation of Amino Alcohols
We report a general and functional-group-tolerant method for the Cu-catalyzed amination of base-sensitive aryl bromides including substrates possessing acidic functional groups and small five-membered heteroarenes. The results presented herein substantially expand the scope of Cu-catalyzed C-N coupling reactions. The combination of L8, an anionic N1,N2-diarylbenzene-1,2-diamine ligand, along with the mild base NaOTMS leads to the formation of a stable yet reactive catalyst that resists deactivation from coordination to heterocycles or charged intermediates. This system enables the use of low catalyst and ligand loadings. Exploiting the differences in nucleophile deprotonation in C-O and C-N coupling reactions catalyzed by Cu·L8 we developed a method to chemoselectively N- and O-arylate a variety of amino alcohol substrates. Employing NaOt-Bu as the base resulted exclusively in C-O coupling when the amino alcohols featured primary alcohols and more hindered amines or aniline groups. Utilizing NaOTMS enabled the ability to override the steric-based selectivity of these reactions completely and exclusively promoted C-N coupling regardless of the structure of the amino alcohol. The ability to invert the observed chemoselectivity is distinct from previously described methods that require protecting group manipulations or rely entirely on steric effects to control reactivity. These results substantially improve the scope of Cu-catalyzed C-N coupling reactions using N1,N2-diarylbenzene-1,2-diamine ligands and introduce a new chemoselective method to arylate amino alcohols.
- 26 June 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (27) , 18616-18625
Cu-Catalyzed Amination of Base-Sensitive Aryl Bromides and the Chemoselective N- and O-Arylation of Amino Alcohols
We report a general and functional-group-tolerant method for the Cu-catalyzed amination of base-sensitive aryl bromides including substrates possessing acidic functional groups and small five-membered heteroarenes. The results presented herein substantially expand the scope of Cu-catalyzed C-N coupling reactions. The combination of L8, an anionic N1,N2-diarylbenzene-1,2-diamine ligand, along with the mild base NaOTMS leads to the formation of a stable yet reactive catalyst that resists deactivation from coordination to heterocycles or charged intermediates. This system enables the use of low catalyst and ligand loadings. Exploiting the differences in nucleophile deprotonation in C-O and C-N coupling reactions catalyzed by Cu·L8 we developed a method to chemoselectively N- and O-arylate a variety of amino alcohol substrates. Employing NaOt-Bu as the base resulted exclusively in C-O coupling when the amino alcohols featured primary alcohols and more hindered amines or aniline groups. Utilizing NaOTMS enabled the ability to override the steric-based selectivity of these reactions completely and exclusively promoted C-N coupling regardless of the structure of the amino alcohol. The ability to invert the observed chemoselectivity is distinct from previously described methods that require protecting group manipulations or rely entirely on steric effects to control reactivity. These results substantially improve the scope of Cu-catalyzed C-N coupling reactions using N1,N2-diarylbenzene-1,2-diamine ligands and introduce a new chemoselective method to arylate amino alcohols.
- 12 January 2022
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 87 (5) , 2559-2568
5-Bromo-2-chloro-4-fluoro-3-iodopyridine as a Halogen-rich Intermediate for the Synthesis of Pentasubstituted Pyridines
The 60 individual halopyridine isomers that contain one bromine, chlorine, fluorine, iodine, and H are valuable potential building blocks in medicinal chemistry research, but surprisingly, there has been only one report on the synthesis of just two of them. Herein, we describe simple syntheses of the unique 5-bromo-2-chloro-4-fluoro-3-iodopyridine (10) and 3-bromo-6-chloro-4-fluoro-2-iodopyridine (32) using halogen dance reactions. C6 magnesiation of 10 and its 3-phenyl analogue 22 followed by trapping with electrophiles generated a variety of pentasubstituted pyridines with desired functionalities for further chemical manipulations.
- 12 January 2022
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 87 (5) , 2559-2568
5-Bromo-2-chloro-4-fluoro-3-iodopyridine as a Halogen-rich Intermediate for the Synthesis of Pentasubstituted Pyridines
The 60 individual halopyridine isomers that contain one bromine, chlorine, fluorine, iodine, and H are valuable potential building blocks in medicinal chemistry research, but surprisingly, there has been only one report on the synthesis of just two of them. Herein, we describe simple syntheses of the unique 5-bromo-2-chloro-4-fluoro-3-iodopyridine (10) and 3-bromo-6-chloro-4-fluoro-2-iodopyridine (32) using halogen dance reactions. C6 magnesiation of 10 and its 3-phenyl analogue 22 followed by trapping with electrophiles generated a variety of pentasubstituted pyridines with desired functionalities for further chemical manipulations.
- 2 July 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (14) , 9786-9874
Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design
Acetals and ketals and their nitrogen and sulfur homologues are often considered to be unconventional and potentially problematic scaffolding elements or pharmacophores for the design of orally bioavailable drugs. This opinion is largely a function of the perception that such motifs might be chemically unstable under the acidic conditions of the stomach and upper gastrointestinal tract. However, even simple acetals and ketals, including acyclic molecules, can be sufficiently robust under acidic conditions to be fashioned into orally bioavailable drugs, and these structural elements are embedded in many effective therapeutic agents. The chemical stability of molecules incorporating geminal diheteroatomic motifs can be modulated by physicochemical design principles that include the judicious deployment of proximal electron-withdrawing substituents and conformational restriction. In this Perspective, we exemplify geminal diheteroatomic motifs that have been utilized in the discovery of orally bioavailable drugs or drug candidates against the backdrop of understanding their potential for chemical lability.
- 2 July 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (14) , 9786-9874
Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design
Acetals and ketals and their nitrogen and sulfur homologues are often considered to be unconventional and potentially problematic scaffolding elements or pharmacophores for the design of orally bioavailable drugs. This opinion is largely a function of the perception that such motifs might be chemically unstable under the acidic conditions of the stomach and upper gastrointestinal tract. However, even simple acetals and ketals, including acyclic molecules, can be sufficiently robust under acidic conditions to be fashioned into orally bioavailable drugs, and these structural elements are embedded in many effective therapeutic agents. The chemical stability of molecules incorporating geminal diheteroatomic motifs can be modulated by physicochemical design principles that include the judicious deployment of proximal electron-withdrawing substituents and conformational restriction. In this Perspective, we exemplify geminal diheteroatomic motifs that have been utilized in the discovery of orally bioavailable drugs or drug candidates against the backdrop of understanding their potential for chemical lability.
- Open Access
- 17 February 2019
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (3) , 312-317
Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481
A triazine hit identified from a screen of the BMS compound collection was optimized for potency, in vivo activity, and off-target profile to produce the bicyclic pyrimidine γ-secretase modulator BMS-932481. The compound showed robust reductions of Aβ1–42 and Aβ1–40 in the plasma, brain, and cerebrospinal fluid of mice and rats. Consistent with the γ-secretase modulator mechanism, increases in Aβ1–37 and Aβ1–38 were observed, with no change in the total amount of Aβ1–x produced. No Notch-based toxicity was observed, and the overall preclinical profile of BMS-932481 supported its further evaluation in human clinical trials.
- 17 February 2019
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (3) , 312-317
Open AccessIdentification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481
A triazine hit identified from a screen of the BMS compound collection was optimized for potency, in vivo activity, and off-target profile to produce the bicyclic pyrimidine γ-secretase modulator BMS-932481. The compound showed robust reductions of Aβ1–42 and Aβ1–40 in the plasma, brain, and cerebrospinal fluid of mice and rats. Consistent with the γ-secretase modulator mechanism, increases in Aβ1–37 and Aβ1–38 were observed, with no change in the total amount of Aβ1–x produced. No Notch-based toxicity was observed, and the overall preclinical profile of BMS-932481 supported its further evaluation in human clinical trials.
- 6 December 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (4) , 659-663
Discovery of new indole-based acylsulfonamide Nav1.7 inhibitors
- 6 December 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (4) , 659-663
Discovery of new indole-based acylsulfonamide Nav1.7 inhibitors
- 16 October 2018
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (3) , 255-260
Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson’s Disease
Herein, we report the discovery of a novel potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM, VU0652957 (VU2957, Valiglurax). VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. To advance toward the clinic, a spray-dried dispersion (SDD) formulation of VU2957 was developed to support IND-enabling toxicology studies. Based on its overall profile, VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson’s disease.
- 16 October 2018
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (3) , 255-260
Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson’s Disease
Herein, we report the discovery of a novel potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM, VU0652957 (VU2957, Valiglurax). VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. To advance toward the clinic, a spray-dried dispersion (SDD) formulation of VU2957 was developed to support IND-enabling toxicology studies. Based on its overall profile, VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson’s disease.
- 1 March 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (5) , 958-962
Discovery of morpholine-based aryl sulfonamides as Nav1.7 inhibitors
- 1 March 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (5) , 958-962
Discovery of morpholine-based aryl sulfonamides as Nav1.7 inhibitors